ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target...
ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target...
PMN310 is an investigational humanized monoclonal antibody (mAb) designed and developed to selectively target soluble amyloid beta oligomers (AβOs), which ProMIS believes to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target Engagement
ProMIS Neurosciences在阿爾茨海默病臨床試驗第17屆臨床試驗會議上展示了PMN310 Phase1a臨床試驗數據；結果顯示PMN310總體上耐受性良好，並且每月一次的投藥可以提供足夠用於靶點介入的腦脊液水平
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement
結果顯示PMN310總體上耐受性良好，並且每月一次的投藥可以提供足夠用於靶點介入的腦脊液水平
Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024
計劃於2024年年底啓動阿爾茨海默病患者1000000000臨床試驗
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place from October 29 – November 1, 2024 in Madrid, Spain.
駐地馬薩諸塞州劍橋和安大略省多倫多，2024年10月30日（全球新聞社）-- ProMIS Neurosciences Inc.（納斯達克股票代碼：PMN），一家專注於針對神經退行性疾病如阿爾茨海默病（AD）、肌萎縮側索硬化（ALS）和多系統萎縮（MSA）中有毒錯誤摺疊蛋白的抗體治療生成和開發的生物技術公司，今天在2024年10月29日至11月1日於西班牙馬德里舉行的第17屆阿爾茨海默病臨床試驗（CTAD）會議上，展示了其首席產品候選藥物PMN310的Phase 1a單升劑量臨床試驗的五個隊列的積極結果。
PMN310 is an investigational humanized monoclonal antibody (mAb) designed and developed to selectively target soluble amyloid beta oligomers (AβOs), which ProMIS believes to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.
PMN310是一種調查性的人源化的單克隆抗體（mAb），旨在選擇性靶向可溶性澱粉樣蛋白β寡聚體（AβOs），ProMIS認爲這是Aβ中最具毒性和病原性的形式，相對於Aβ單體和澱粉樣斑塊。
譯文內容由第三人軟體翻譯。
